Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T15739
(Former ID: TTDC00118)
|
|||||
Target Name |
Cellular tumor antigen p53 (TP53)
|
|||||
Synonyms |
Tumor suppressor p53; Phosphoprotein p53; P53; Antigen NY-CO-13
|
|||||
Gene Name |
TP53
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 3 Target-related Diseases | + | ||||
1 | Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] | |||||
2 | Transplant rejection [ICD-11: NE84] | |||||
3 | Ovarian dysfunction [ICD-11: 5A80] | |||||
Function |
Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2. Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type.
Click to Show/Hide
|
|||||
UniProt ID | ||||||
Sequence |
MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE RCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS SCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
ADReCS ID | BADD_A02521 ; BADD_A03004 ; BADD_A05675 ; BADD_A06440 ; BADD_A08298 | |||||
HIT2.0 ID | T82JWE |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 17 Clinical Trial Drugs | + | ||||
1 | Contusugene ladenovec | Drug Info | Phase 3 | Oral cancer | [2] | |
2 | QPI-1002 | Drug Info | Phase 3 | Renal transplantation | [3] | |
3 | Thymoquinone | Drug Info | Phase 2/3 | Polycystic ovarian syndrome | [4] | |
4 | Ad-p53 | Drug Info | Phase 2 | Solid tumour/cancer | [5] | |
5 | ALT-801 | Drug Info | Phase 2 | Acute myeloid leukaemia | [6] | |
6 | APG-115 | Drug Info | Phase 2 | Prolymphocytic leukaemia | [7] | |
7 | APR-246 | Drug Info | Phase 2 | Ovarian cancer | [8] | |
8 | INGN-225 | Drug Info | Phase 2 | Head and neck cancer | [9] | |
9 | Kevetrin | Drug Info | Phase 2 | Ovarian cancer | [8] | |
10 | SGT-53 | Drug Info | Phase 2 | Pancreatic cancer | [8] | |
11 | ISA-P53-01 | Drug Info | Phase 1/2 | Colorectal cancer | [10] | |
12 | CGM097 | Drug Info | Phase 1 | Solid tumour/cancer | [11] | |
13 | COTI-2 | Drug Info | Phase 1 | Cervical cancer | [8] | |
14 | Dendritic cell vaccine | Drug Info | Phase 1 | Head and neck cancer | [12] | |
15 | HDM201 | Drug Info | Phase 1 | Haematological malignancy | [13] | |
16 | ONYX-015 | Drug Info | Phase 1 | Head and neck cancer | [14] | |
17 | SAR-405838 | Drug Info | Phase 1 | Solid tumour/cancer | [15] | |
Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
1 | INGN-234 | Drug Info | Discontinued in Phase 2 | Oral cancer | [16] | |
2 | Pifithrin-alpha | Drug Info | Terminated | Toxicity | [17] | |
3 | TAR-1 | Drug Info | Terminated | Solid tumour/cancer | [18] | |
Mode of Action | [+] 5 Modes of Action | + | ||||
Modulator | [+] 7 Modulator drugs | + | ||||
1 | Contusugene ladenovec | Drug Info | [1] | |||
2 | QPI-1002 | Drug Info | [19] | |||
3 | Ad-p53 | Drug Info | [21] | |||
4 | CGM097 | Drug Info | [19] | |||
5 | COTI-2 | Drug Info | [8] | |||
6 | ONYX-015 | Drug Info | [28], [29] | |||
7 | SAR-405838 | Drug Info | [30], [31] | |||
Inhibitor | [+] 7 Inhibitor drugs | + | ||||
1 | Thymoquinone | Drug Info | [20] | |||
2 | APG-115 | Drug Info | [8] | |||
3 | HDM201 | Drug Info | [27] | |||
4 | Pifithrin-alpha | Drug Info | [33] | |||
5 | 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine | Drug Info | [35] | |||
6 | NU-8231 | Drug Info | [36] | |||
7 | NUTLIN-3 | Drug Info | [37] | |||
Immunomodulator (Immunostimulant) | [+] 1 Immunomodulator (Immunostimulant) drugs | + | ||||
1 | ALT-801 | Drug Info | [6] | |||
Stimulator | [+] 3 Stimulator drugs | + | ||||
1 | APR-246 | Drug Info | [22] | |||
2 | Kevetrin | Drug Info | [8] | |||
3 | SGT-53 | Drug Info | [24] | |||
Suppressor | [+] 1 Suppressor drugs | + | ||||
1 | INGN-234 | Drug Info | [32] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-regulating Transcription Factors | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) | ||||||
Drug Resistance Mutation (DRM) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61. | |||||
REF 2 | ClinicalTrials.gov (NCT00041613) Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate. U.S. National Institutes of Health. | |||||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 4 | ClinicalTrials.gov (NCT04852510) Amelioration of Polycystic Ovary Syndrome Related Disorders by Supplementation of Thymoquinone and Metformin. U.S. National Institutes of Health. | |||||
REF 5 | ClinicalTrials.gov (NCT03544723) Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.. U.S. National Institutes of Health. | |||||
REF 6 | Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. | |||||
REF 7 | ClinicalTrials.gov (NCT04496349) A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL. U.S. National Institutes of Health. | |||||
REF 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019096) | |||||
REF 10 | Clinical pipeline report, company report or official report of ISA Pharmaceuticals BV. | |||||
REF 11 | ClinicalTrials.gov (NCT01760525) A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
REF 12 | ClinicalTrials.gov (NCT00404339) Vaccine Therapy in Treating Patients With Head and Neck Cancer. U.S. National Institutes of Health. | |||||
REF 13 | ClinicalTrials.gov (NCT02143635) Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt. U.S. National Institutes of Health. | |||||
REF 14 | ClinicalTrials.gov (NCT00006106) ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer. U.S. National Institutes of Health. | |||||
REF 15 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036509) | |||||
REF 16 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028790) | |||||
REF 17 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012866) | |||||
REF 18 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031168) | |||||
REF 19 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 20 | Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. | |||||
REF 21 | Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38. | |||||
REF 22 | APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. | |||||
REF 23 | INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. | |||||
REF 24 | Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8. | |||||
REF 25 | WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. | |||||
REF 26 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. | |||||
REF 27 | National Cancer Institute Drug Dictionary (drug id 761551). | |||||
REF 28 | Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23. | |||||
REF 29 | Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000 Nov 15;60(22):6359-66. | |||||
REF 30 | SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. | |||||
REF 31 | SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.Clin Cancer Res.2016 Mar 1;22(5):1150-60. | |||||
REF 32 | Prevent Oral Cancer With Mouthwash. Introgen Therapeutics. | |||||
REF 33 | An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77. | |||||
REF 34 | Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86. | |||||
REF 35 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 36 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21. | |||||
REF 37 | Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein intera... J Med Chem. 2009 Nov 26;52(22):7044-53. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.